港股最大造假？4000名投资者血本无归

Core Viewpoint - The article discusses the downfall of Nohui Health, once hailed as the "first stock in cancer screening," which faced severe financial and operational issues leading to its delisting after over 500 days of suspension [5][31]. Group 1: Company Background and Rise - Nohui Health was founded in 2015 by three Peking University alumni, focusing on early cancer screening, particularly for colorectal cancer, addressing a significant market need in China [25][26]. - The company launched its first product, "Changweiqing," in 2016, which was a non-invasive home screening tool for colorectal cancer, gaining attention in the industry [26][27]. - By 2021, Nohui Health went public on the Hong Kong Stock Exchange, raising approximately 2 billion HKD and achieving a market capitalization of over 41 billion HKD on its first day of trading [28]. Group 2: Financial Misconduct and Downfall - In August 2023, a short-selling report from CapitalWatch accused Nohui Health of inflating revenues by over 300 million CNY in 2022 through questionable sales practices [8][10]. - The report claimed that the actual sales revenue for 2022 was only 76.95 million CNY, a stark contrast to the reported 765 million CNY, indicating a nearly ninefold discrepancy [8]. - Deloitte's refusal to endorse Nohui Health's financial statements and subsequent resignation as auditor raised significant concerns about the company's financial integrity [12][14]. Group 3: Impact on Investors - Nohui Health's delisting resulted in a market value loss exceeding 33.6 billion HKD, leaving investors with a valuation of just 0.01 HKD [31][34]. - The complex corporate structure of Nohui Health, registered in the Cayman Islands and listed in Hong Kong, complicated the legal recourse for mainland investors, many of whom faced total losses [35][37]. - Over 4,000 individual investors have registered for potential claims, with total investments exceeding 700 million CNY, highlighting the widespread financial impact of the company's collapse [36][39].